ABSTRACT

Background: To analyze the efficacy and safety of dendritic cell – cytokine – induced killer (DC-CIK) immunotherapy combined with chemotherapy for colorectal cancer. Method: A retrospective analysis was conducted in 116 patients from February 2012 to December 2017, who were divided into postoperative adjuvant chemotherapy group alone, combined DC-CIK immunotherapy group, advanced cancer palliative care group, and palliative care + DC-CIK immunotherapy group, to evaluate cellular immune function, disease-free survival(DFS) and overall survival(OS). Results: In the adjuvant therapy and palliative care group, the percentages of CD3+, CD8+ and NK cells after treatment were significantly lower than before, whereas in the other two groups given DC-CIK immunotherapy, the percentages of CD3+, CD8+, NK and NKT cells after treatment were all higher than before, with a significant increase compared with the chemotherapy group (P < .05). DFS (42.4 ± 5.26 m) in the group receiving postoperative adjuvant chemotherapy + DC-CIK immunotherapy was significantly longer than that (23.5 ± 2.79 m) in the group only given postoperative adjuvant chemotherapy (P < .05). OS in the group receiving palliative care + DC-CIK immunotherapy was slightly longer than that in the group only given palliative care for advanced cancer (29 m vs 26 m, P > .05).Conclusion: Combination with DC-CIK immunotherapy could effectively improve cellular immune function. Postoperative adjuvant chemotherapy in combination with DC-CIK immunotherapy could significantly prolong DFS, but palliative care in combination with DC-CIK immunotherapy did not significantly prolong OS in patients with advanced cancer.

摘要

背景：分析树突状细胞-细胞因子-诱导杀伤（DC-CIK）免疫疗法联合化疗治疗结直肠癌的疗效和安全性。方法：回顾性分析2012年2月至2017年12月116例患者，分为术后单纯辅助化疗组、联合DC-CIK免疫治疗组、晚期癌症姑息治疗组、姑息治疗+DC-CIK免疫治疗组。评估细胞免疫功能、无病生存（DFS）和总生存（OS）。结果：在辅助治疗和姑息治疗组中，治疗后CD3+、CD8+和NK细胞的百分比明显低于治疗前，而在接受DC-CIK免疫治疗的其他两组中，治疗后CD3+、CD8+、NK和NKT细胞的百分比治疗组均高于治疗前，与化疗组相比显着增加（P < .05）。术后辅助化疗+DC-CIK免疫治疗组的DFS（42.4±5.26 m）显着长于仅术后辅助化疗组（23.5±2.79 m）（P < .05）。接受姑息治疗+DC-CIK免疫治疗组的OS略长于仅接受姑息治疗的晚期癌症组（29 m vs 26 m，P> .05）。结论：联合DC-CIK免疫疗法可有效改善细胞免疫功能。术后辅助化疗联合 DC-CIK 免疫治疗可显着延长 DFS，但姑息治疗联合 DC-CIK 免疫治疗并未显着延长晚期癌症患者的 OS。